Skip to main content

Table 1 Open clinical trials of CAR-T-cell therapy for patients with CLL

From: Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

ClinicalTrials ID Trial title/description Target
NCT02640209 Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) CD19
NCT02644655 Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia CD19
NCT02456350 Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies CD19
NCT03076437 Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies CD19
NCT01865617 Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia CD19
NCT02933775 CD19-redirected Autologous Cells (CAR-CD19 T Cells) CD19
NCT02672501 A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia CD19
NCT01853631 Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) CD19
NCT03110640 Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma CD19
NCT01747486 CD19 Redirected Autologous T Cells CD19
NCT03085173 A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies CD19
NCT02685670 Competitive Transfer of #CD19-TCRz-CD28 and #CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma CD19
NCT02782351 Humanized CAR-T Therapy for Treatment of B Cell Malignancy CD19
NCT00881920 Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Kappa
NCT02050347 Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) CD19
NCT02963038 CAR T Cells for Refractory B Cell Malignancy CD19
NCT03068416 CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy CD19
NCT03166878 A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma CD19
NCT03448393 CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22
NCT03191773 A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies CD19
NCT02132624 CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial CD19
NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas CD20
NCT02851589 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma CD19
NCT02819583 CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma CD19
NCT03302403 Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors CD19
NCT02706392 Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies ROR1
NCT01626495 Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma CD19
NCT01475058 CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant CD19
NCT03331198 Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004) CD19
NCT01593696 Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma CD19
NCT03436771 Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product CD19
NCT01864889 Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 CD19
NCT03050190 A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies CD19